Elizabeth (Beth) White, Ph.D., is Assistant Vice President, Rare Disease Commercial Development for Pfizer’s Global Innovative Pharma Business. In this role, Beth leads the development and execution of new product strategy for Pfizer Rare Disease, working closely with both R&D and business development, and managing a team of Directors who focus on the Neuromuscular, Hematologic, and Pulmonary disease areas. Beth also leads Pfizer’s efforts in gene therapy, chairing a cross-functional working group that is developing a long-term strategy for Pfizer’s end-to-end efforts in gene therapy.
Beth has a unique blend of business and scientific skills, gained during more than 26 years in the biopharmaceutical industry (18 years at Wyeth/Pfizer), and is skilled in developing high-performing cross-functional teams to tackle many different strategic, stakeholder engagement, policy, and communications challenges. Throughout her career in small to large pharmaceutical companies, she has held a wide range of positions covering the drug development and commercialization continuum across many different disease areas, including strategic planning, new product commercial planning, research & development, life cycle management, and global brand leadership.
Beth received her B.S. degree in Biology from Allegheny College. She holds M.S. and Ph.D. degrees from the University of Rochester, with a concentration in Molecular and Cellular Biology.